

Mariana ChÃ¡vez-MacGregor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5836172/publications.pdf>

Version: 2024-02-01

116
papers

7,327
citations

94269

37
h-index

58464

82
g-index

117
all docs

117
docs citations

117
times ranked

10034
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2022, 29, 686-696.	0.7	11
2	Use of Biosimilar Medications in Oncology. <i>JCO Oncology Practice</i> , 2022, 18, 177-186.	1.4	15
3	Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients: A Qualitative Analysis. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 749-759.	0.8	3
4	Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 863.	3.4	6
5	Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study. <i>Cancer</i> , 2022, 128, 3243-3253.	2.0	3
6	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 685-693.	0.8	66
7	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e230-e240.	1.9	3
8	The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa—Maternal Orphans and a Cycle of Disadvantage. <i>JAMA Oncology</i> , 2021, 7, 197.	3.4	2
9	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
10	Adjuvant tamoxifen adherence in men with early-stage breast cancer. <i>Cancer</i> , 2021, , .	2.0	7
11	Impact of SSO-ASTRO “No Ink on Tumor” Guidelines on Reexcision Rates among Older Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 3703-3713.	0.7	4
12	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020, 27, 359-366.	0.7	5
13	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. <i>Annals of Surgical Oncology</i> , 2020, 27, 2229-2237.	0.7	6
14	Delayed initiation of adjuvant chemotherapy in older women with breast cancer. <i>Cancer Medicine</i> , 2020, 9, 6961-6971.	1.3	20
15	Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?. <i>Plastic and Reconstructive Surgery</i> , 2020, 146, 945-953.	0.7	9
16	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 749-757.	1.9	28
17	Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. <i>Cancer</i> , 2020, 126, 3929-3938.	2.0	10
18	Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2020, 25, 937-942.	1.9	6

#	ARTICLE	IF	CITATIONS
19	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020, 15, e0229903.	1.1	23
20	Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms. <i>Cancer</i> , 2020, 126, 3456-3463.	2.0	3
21	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2 ⁺ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	3.2	11
22	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	2.2	141
23	Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. <i>Drugs and Aging</i> , 2019, 36, 341-354.	1.3	20
24	Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2019, 26, 2730-2737.	0.7	27
25	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351.	1.2	28
26	Ductal Carcinoma In Situ and Margins $\leq 5\text{mm}$. <i>Annals of Surgery</i> , 2019, 269, 150-157.	2.1	29
27	Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. <i>Cancer</i> , 2018, 124, 1760-1769.	2.0	9
28	Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1786-1787.	0.7	8
29	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 267, 946-951.	2.1	147
30	Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. <i>Cancer</i> , 2018, 124, 899-906.	2.0	30
31	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 203.	3.4	152
32	Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. <i>Cancer</i> , 2018, 124, 679-687.	2.0	35
33	ASCO Resource-Stratified Guidelines: Methods and Opportunities. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
34	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	0.8	131
35	Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. <i>Cancer</i> , 2018, 124, 4685-4691.	2.0	2
36	Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1084-1093.	2.3	93

#	ARTICLE	IF	CITATIONS
37	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018, 10, 296-306.	0.5	5
38	American Society of Breast Surgeons™ Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. <i>Annals of Surgical Oncology</i> , 2018, 25, 2965-2974.	0.7	16
39	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309.	1.9	46
40	Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. <i>Clinical Neurology and Neurosurgery</i> , 2018, 173, 61-64.	0.6	7
41	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , 2017, 116, 509-514.	2.9	18
42	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017, 123, 2422-2431.	2.0	19
43	Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgery</i> , 2017, 265, 574-580.	2.1	21
44	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509.	3.4	154
45	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	42
46	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017, 123, 3367-3376.	2.0	13
47	Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage. <i>JAMA Oncology</i> , 2017, 3, 1425.	3.4	2
48	Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. <i>Academic Radiology</i> , 2017, 24, 191-199.	1.3	8
49	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017, 61, 53-60.	3.4	39
50	All HER2-Positive Tumors are not Created Equal. <i>Annals of Surgical Oncology</i> , 2017, 24, 3471-3474.	0.7	4
51	Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. <i>Annals of Surgical Oncology</i> , 2017, 24, 3502-3509.	0.7	44
52	Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. <i>Lancet Oncology</i> , The, 2017, 18, 1568-1569.	5.1	1
53	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. <i>Oncologist</i> , 2017, 22, 1292-1300.	1.9	84
54	Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement. <i>Annals of Surgical Oncology</i> , 2017, 24, 1-2.	0.7	32

#	ARTICLE	IF	CITATIONS
55	Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. <i>Cancer</i> , 2017, 123, 940-947.	2.0	22
56	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. <i>Journal of Cancer</i> , 2017, 8, 2653-2662.	1.2	38
57	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. <i>Practical Radiation Oncology</i> , 2016, 6, 287-295.	1.1	135
58	The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 696-703.	1.1	38
59	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3557-3565.	1.0	32
60	Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3501-3509.	0.7	54
61	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 21-27.	1.9	19
62	Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 339-350.	1.1	14
63	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 637-644.	0.4	1
64	Estimating regimenâ€“specific costs of chemotherapy for breast cancer: Observational cohort study. <i>Cancer</i> , 2016, 122, 3447-3455.	2.0	23
65	Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 367-374.	1.1	23
66	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2016, 34, 4040-4046.	0.8	211
67	Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2016, 23, 3801-3810.	0.7	176
68	Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. <i>Journal of Clinical Oncology</i> , 2016, 34, 1072-1078.	0.8	626
69	Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 322.	3.4	267
70	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 929.	3.4	94
71	Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. <i>Biomarkers in Medicine</i> , 2016, 10, 315-328.	0.6	5
72	Randomized Clinical Trials and Observational Studies: Is There a Battle?. <i>Journal of Clinical Oncology</i> , 2016, 34, 772-773.	0.8	38

#	ARTICLE	IF	CITATIONS
73	Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. <i>Supportive Care in Cancer</i> , 2016, 24, 2695-2706.	1.0	6
74	Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 1515-1521.	0.7	86
75	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016, 7, 76362-76373.	0.8	22
76	Barriers to the Use of Breast Cancer Risk Reduction Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 927-935.	2.3	19
77	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015, 6, 310-318.	1.2	20
78	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2239-2245.	0.8	104
79	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 407-416.	1.1	68
80	Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2176-2183.	0.8	93
81	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. <i>Clinical Breast Cancer</i> , 2015, 15, 153-160.	1.1	33
82	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2015, 144, 713-721.	0.4	34
83	Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 417-423.	1.1	27
84	Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 90-95.	0.7	34
85	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614.	0.8	34
86	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. <i>Lancet Oncology</i> , The, 2014, 15, e625-e634.	5.1	186
87	Society of Surgical Oncology's American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 704-716.	0.7	348
88	Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 316-323.	1.1	18
89	Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: Is There a Way Forward for Sentinel Lymph Node Dissection in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2014, 21, 2468-2473.	0.7	53
90	Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 735-744.	0.8	237

#	ARTICLE	IF	CITATIONS
91	Society of Surgical Oncologyâ€”American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1507-1515.	0.8	369
92	Society of Surgical Oncologyâ€”American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 553-564.	0.4	364
93	Frequency of mesenchymalâ€”epithelial transition factor gene (<i>MET</i>) and the catalytic subunit of phosphoinositideâ€”kinase (<i>PIK3CA</i>) copy number elevation and correlation with outcome in patients with early stage breast cancer. <i>Cancer</i> , 2013, 119, 7-15.	2.0	49
94	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. SpringerPlus, 2013, 2, 409.	1.2	21
95	Tamoxifen therapy for patients with breast cancer. <i>Lancet</i> , The, 2013, 381, 2077-2078.	6.3	2
96	New drugs, new knowledge, new targets. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 75-76.	12.5	9
97	Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 378-384.	1.1	32
98	Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4222-4228.	0.8	207
99	Two Birds With One Stone: Octreotide Treatment for Acromegaly and Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, e398-e400.	0.8	6
100	Male breast cancer according to tumor subtype and race. <i>Cancer</i> , 2013, 119, 1611-1617.	2.0	91
101	Adjuvant bisphosphonates in breast cancer: has the time come?. <i>Breast Cancer Management</i> , 2013, 2, 327-337.	0.2	0
102	Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. <i>Journal of Cancer</i> , 2013, 4, 549-556.	1.2	34
103	cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes. <i>Clinical Cancer Research</i> , 2012, 18, 2269-2277.	3.2	108
104	Everolimus in the treatment of hormone receptor-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1835-1843.	1.9	10
105	Bisphosphonates and pathologic complete response to taxaneâ€”and anthracyclineâ€”based neoadjuvant chemotherapy in patients with breast cancer. <i>Cancer</i> , 2012, 118, 326-332.	2.0	10
106	Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. <i>Clinical Breast Cancer</i> , 2011, 11, 325-331.	1.1	62
107	Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer. <i>Cancer</i> , 2011, 117, 3641-3649.	2.0	16
108	Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2628-2634.	0.8	128

#	ARTICLE	IF	CITATIONS
109	Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2645-2652.	0.8	400
110	Breast cancer, neoadjuvant chemotherapy and residual disease. <i>Clinical and Translational Oncology</i> , 2010, 12, 461-467.	1.2	17
111	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy. <i>Cancer</i> , 2010, 116, 4168-4177.	2.0	44
112	Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 421-428.	5.1	253
113	Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 101-112.	1.1	38
114	Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: a case-control analysis. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 147-152.	1.1	35
115	Angiogenesis in the Bone Marrow of Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5396-5400.	3.2	34
116	Postmenopausal Breast Cancer Risk and Cumulative Number of Menstrual Cycles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 799-804.	1.1	53